{
  "LONN.SW": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Diagnostics & Research",
    "long_name": "Lonza Group Ltd",
    "market": "ch_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "LONZA N",
    "state": null,
    "summary": "Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment engages in the microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.",
    "website": "http://www.lonza.com",
    "zipcode": "4002"
  },
  "LZAGF": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Lonza Group Ltd",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "LONZA GROUP AG",
    "state": null,
    "summary": "Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment engages in the microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.",
    "website": "http://www.lonza.com",
    "zipcode": "4002"
  },
  "LZAGY": {
    "city": "Basel",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Lonza Group Ltd",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "LONZA GROUP AG",
    "state": null,
    "summary": "Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment engages in the microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.",
    "website": "http://www.lonza.com",
    "zipcode": "4002"
  },
  "QTNT": {
    "city": "Eysins",
    "country": "Switzerland",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Diagnostics & Research",
    "long_name": "Quotient Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Quotient Limited",
    "state": null,
    "summary": "Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.",
    "website": "http://www.quotientbd.com",
    "zipcode": "1262"
  },
  "U4W.F": {
    "city": "Eysins",
    "country": "Switzerland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Quotient Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "QUOTIENT LTD",
    "state": null,
    "summary": "Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.",
    "website": "http://www.quotientbd.com",
    "zipcode": "1262"
  }
}
